Pyridam Farma Valuation

Is PYFA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of PYFA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate PYFA's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate PYFA's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for PYFA?

Key metric: As PYFA is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for PYFA. This is calculated by dividing PYFA's market cap by their current revenue.
What is PYFA's PS Ratio?
PS Ratio	2.3x
Sales	Rp1.34t
Market Cap	Rp3.07t

PYFA key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	4.8x
Enterprise Value/EBITDA	-178x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does PYFA's PS Ratio compare to its peers?

The above table shows the PS ratio for PYFA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	0.9x
KAEF Kimia Farma	0.3x	n/a	Rp3.4t
DVLA Darya-Varia Laboratoria	0.9x	n/a	Rp1.8t
MERK Merck	1.6x	n/a	Rp1.5t
SOHO Soho Global Health	0.9x	n/a	Rp8.8t
PYFA Pyridam Farma	2.3x	n/a	Rp3.1t

Price-To-Sales vs Peers: PYFA is expensive based on its Price-To-Sales Ratio (2.3x) compared to the peer average (0.9x).

Price to Sales Ratio vs Industry

How does PYFA's PS Ratio compare vs other companies in the Asian Pharmaceuticals Industry?

48 Companies	Price / Sales	Estimated Growth	Market Cap

48 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: PYFA is good value based on its Price-To-Sales Ratio (2.3x) compared to the Asian Pharmaceuticals industry average (2.7x).

Price to Sales Ratio vs Fair Ratio

What is PYFA's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PYFA PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	2.3x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate PYFA's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.